+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07503834

Evaluating Safety of Anakinra to Prevent Immunothrombosis After Pancreatic Transplantation at Nantes University Hospital

Led by Nantes University Hospital · Updated on 2026-10-13

15

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This clinical trial evaluates the safety of Anakinra, an IL-1 blocking drug, in patients who have recently undergone pancreatic transplantation. Pancreas transplantation aims to cure diabetes by restoring insulin production, but early graft loss due to immune-related blood clots remains a significant challenge. The study focuses on whether adding IL-1 blockade to standard care can improve safety outcomes after transplant. Participants receive Anakinra starting immediately after their pancreas transplant, either alone or combined with a kidney transplant if applicable. The trial is open-label and non-randomized, conducted at a single center, and spans Phase III. The treatment period and assessments extend up to one year post-transplant to monitor safety and graft function. During the study, participants will be regularly evaluated for safety, including infections and rejection episodes. Researchers will assess patient survival, pancreatic and renal graft survival and function, and the presence of graft-specific antibodies. The trial includes monitoring for bacterial, viral, and fungal infections, with follow-up lasting one year to gather comprehensive safety and efficacy data.

CONDITIONS

Brief Title

"IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"

Research Team

C

Christophe MASSET

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here